Future Oncology未来肿瘤学
Future Oncology(英文缩写 FUTURE ONCOL),ISSN 1479-6694,eISSN 1744-8301,中文译名:未来肿瘤学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.674 | Q3 |
| 2022 | 3.300 | Q3 |
| 2023 | 3.000 | Q2 |
| 2024 | 2.600 | Q3 |
| 2025 | 3.100 | Q2 |
Future Oncology 最新收录文献
-
2. Beyond survival: advancing psycho-oncology research on fear of recurrence or progression.
PMID:日期:2026-09-23该文献暂无摘要。
-
4. First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study.
PMID:日期:2026-09-22In this podcast, over a series of four parts, the authors provide an overview of the CheckMate 9DW study (NCT04039607) in hepatocellular carcinoma (HCC) and their opinions on how it impacts the treatment landscape for first-line unresectable HCC. The first two parts provide an overview of the primary safety and efficacy data from CheckMate 9DW as well as key sub-group analyses and additional findings. The third part focuses on the early crossing phenomenon of the overall survival Kaplan-Meier (KM) curves and discussion of potential contributors. The fourth part discusses the management of adverse events, the timing of immune‑mediated adverse events, and the impact of discontinuation and steroid use on efficacy. Across all parts, implications for clinical practice will be discussed, including topics such as patient selection, sequencing of therapies, immune-mediated toxicities, monitoring recommendations, and real-world considerations.
-
6. A patient's experience with follicular lymphoma from diagnosis to cure: the life-changing impact of CAR T-cell therapy.
PMID:日期:2026-09-22In this patient perspective, Laurie Adami describes her experience with follicular lymphoma (FL), from diagnosis to cure. After diagnosis in 2006, Laurie underwent continuous treatments with 6 therapies over 12 years, all resulting in disease relapse and progression. Some treatments left her with lifelong side effects. In 2018, with extensive tumor burden and nearing kidney failure, Laurie enrolled in the ZUMA-5 clinical trial (NCT03105336) and received her seventh and final treatment, a chimeric antigen receptor (CAR) T-cell therapy called axicabtagene ciloleucel (axi-cel). Just 30 days after her axi-cel infusion, imaging revealed her cancer had vanished, and she remains cancer-free to this day, about 8 years later. Laurie did experience severe side effects to treatment. This is attributable, in part, because she received CAR T-cell therapy in its earlier days before protocols were developed to treat and also mitigate common side effects. However, all her side effects from CAR T-cell therapy resolved, and her quality of life returned to her pre-infusion state within 3-4 months. By sharing her experience, Laurie aims to raise awareness for this life-saving and likely curative treatment across multiple audiences that may be impacted by FL, including patients, clinicians, families/caregivers, and advocates.
-
7. The role of contrast enhanced ct plus pan-immune-inflammation value in predicting outcomes of hepatocellular carcinoma after hepatectomy.
PMID:日期:2026-09-21Early recurrence after hepatectomy remains a major challenge for hepatocellular carcinoma (HCC). This study evaluated the prognostic value of preoperative pan-immune-inflammation value (PIV) for predicting early recurrence after curative-intent HCC resection. This study retrospectively included 86 patients with histologically confirmed HCC who underwent hepatectomy. The optimal PIV cutoff for predicting recurrence or metastasis within 24 months was determined. Multivariate logistic regression was used to identify predictors of 2-year recurrence. 27 patients experienced recurrence or metastasis within 24 months after surgery. The optimal PIV cutoff was 105.91, with an area under the curve (AUC) of 0.758. Patients with high PIV had shorter progression-free survival than those with low PIV (18.37 months versus 23.93 months). High PIV was independently associated with poorer progression-free survival. High PIV, tumor diameter > 50 mm, and microvascular invasion were independently associated with 2-year recurrence. A three-tier model combining PIV status and tumor size stratified patients into low-, intermediate-, and high-risk groups, with corresponding 24-month recurrence rates of 4.8%, 22.9%, and 60.0%, respectively. The combined predictive model achieved an AUC of 0.861. Preoperative PIV may serve as a readily accessible biomarker for identifying patients at increased risk of early recurrence after hepatocellular carcinoma resection.
-
8. Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.
PMID:日期:2026-09-20Platinum-based chemotherapy (PBC) followed by avelumab first-line (1L) maintenance for patients with nonprogressive disease is a standard of care in locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic. We report results from a retrospective analysis of a national reimbursement registry for avelumab maintenance. The objective was to assess the effectiveness and safety in routine clinical practice. Registry data were collected between October 2021 and January 2024. Primary endpoint was overall survival (OS) from avelumab 1L maintenance; secondary endpoints included progression-free survival (PFS) and safety. At data cutoff, 107 patients with la/mUC were treated with avelumab 1L maintenance, the median age was 72 years (range, 45-92), and the median follow-up was 8.2 months. Fifty-five patients (51.4%) received 1L cisplatin-based chemotherapy, 46 (43.0%) carboplatin-based chemotherapy, and six (5.6%) switched between regimens. Median OS was not reached, the 12- and 18-month OS rates were 79.3% and 68.0%. Limitations include low number of patients, retrospective design, and short follow-up. These clinical outcomes are consistent with the JAVELIN Bladder 100 trial and other real-world studies, supporting the effectiveness and favorable safety profile of avelumab as 1L maintenance in patients with la/mUC that has not progressed with 1L PBC.
-
9. Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis.
PMID:日期:2026-09-19Advanced or metastatic soft-tissue sarcoma (STS) responds poorly to standard chemotherapy. Anlotinib has shown activity across multiple treatment lines, including first-line and maintenance therapies, though monotherapy benefit remains limited. This study aimed to quantify the efficacy of anlotinib plus PD-1/PD-L1 inhibitors in advanced or metastatic soft-tissue sarcoma (STS). We conducted a PRISMA-adherent systematic review of PubMed, Scopus, and Web of Science from inception to October 2025. Studies enrolling adults with advanced or metastatic STS treated with anlotinib plus a PD-1/PD-L1 inhibitor were eligible. Pooled analyses were performed in R using the meta package under inverse-variance random-effects models. Seven studies were included. The pooled objective response rate was 37.3% (95% CI, 17.0-60.4), and the pooled disease control rate was 77.2% (95% CI, 71.7-82.4). Complete and partial responses occurred in 4.3% (95% CI, 1.4-8.8) and 29.9% (95% CI, 13.4-49.6), respectively, with stable disease in 50.6% (95% CI, 39.5-61.8). The pooled 6-month progression-free survival (PFS-6) rate was 61.1% (95% CI, 22.1-93.1). Among advanced or metastatic STS cohorts, combination therapy with anlotinib and PD-1/PD-L1 inhibitors showed encouraging objective responses and disease control. These outcomes appeared numerically higher than those historically reported with monotherapy, although the evidence remains limited by small sample sizes, non-randomized designs, and histologic heterogeneity. PROSPERO (URL: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251232427), identifier is CRD420251232427.
-
10. MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.
10. MH-Penile-002：一项新辅助抗EGFR抗体偶联药物联合PD-1抑制剂治疗保阴茎困难或区域淋巴结转移阴茎癌的II期、前瞻性、单臂试验PMID:日期:2026-09-18Emerging evidence suggests that combinations of antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) may be effective for advanced penile squamous cell carcinoma (PSCC). These findings support the translation of this strategy into the neoadjuvant setting, offering a novel approach for patients with locally advanced or regionally metastatic disease who have limited treatment options. This single-center, prospective, single-arm, phase II trial evaluates the efficacy and safety of neoadjuvant Becotatug Vedotin plus Pucotenlimab in EGFR-expressing PSCC patients with challenging penile preservation or regional lymph node metastasis. Utilizing a Simon's two-stage design, the primary endpoint is the investigator-assessed R0 resection rate. Secondary endpoints include the downstaging rate, objective response rate (ORR), pathological complete response (pCR) rate, major pathological response (MPR) rate, tumor regression grade (TRG), event-free survival (EFS), disease-free survival (DFS), and organ‑sparing rate. The study plans to enroll 60 patients with EGFR-expressing PSCC. Clinical trial registration: www.clinicaltrials.gov identifier is NCT07518979.